BD (NYSE: BDX) posted second-quarter results today that beat the consensus forecast on Wall Street, increasing its full-year guidance. The medtech giant, however, also acknowledged that it’s seeing the COVID-19 delta variant impact elective procedure volumes in some U.S. states. Get the full story on our sister site MassDevice.
BD
BD begins remediation in Alaris infusion system software recall
BD (NYSE:BDX) announced today that it will begin remediation for a 2020 Class I-level recall of its Alaris infusion system. Franklin Lakes, N.J.–based BD has had shipments of Alaris pumps on hold after the FDA called for a comprehensive 510(k) submission to cover a host of software fixes, with pumps only going to health providers […]
BD announces two new directors for diabetes spinoff
BD (NYSE:BDX) announced today that it appointed David F. Melcher and Dr. Claire Pomeroy as directors of its diabetes spinoff. Franklin Lakes, N.J.-based BD previously announced the separation of its diabetes care business into an independent, publicly traded company called NewCo. According to a news release, the appointments of Melcher as non-executive chair of the […]
BD surpasses 2 billion orders for COVID-19 vaccine injection devices
BD (NYSE:BDX) announced today that orders for its needles and syringes hit 2 billion amid global COVID-19 vaccination efforts. Franklin Lakes, N.J.-based BD’s latest milestone comes less than six months after the company surpassed 1 million orders for vaccine delivery devices. The order total encompasses commitments to governments all over the globe, including the U.S., […]
BD applicators cited in medical kit recall
A medical care kit company is recalling more than 8,200 kits because they contain BD applicators that may become contaminated with a fungus. The recall by Medical Action Industries covers certain of its 306 Medical Convenience Kits, distributed between December 12, 2019, and March 22, 2021, according to the FDA. The agency has labeled the […]
BD to build $200M facility in Spain for pre-filled drug delivery device manufacturing
BD (NYSE:BDX) announced today that it will build a more than $200 million drug delivery device manufacturing facility in Spain. The approximately $201.5 million (€165 million) high-tech manufacturing facility in Zaragoza, Spain, is expected to create up to 600 jobs by 2030, according to a news release. In December, BD announced its plan to invest […]
BD to spin off its diabetes business, Q2 earnings beat The Street
BD (NYSE: BDX) announced today that it will spin off its Diabetes Care business as an independent, publicly traded company during the first half of 2022. The Diabetes Care business saw $1.1 billion in sales during BD’s fiscal year ended Sept. 30, 2020, nearly half outside the U.S. The business manufactures roughly 8 billion injection […]
BD’s Alaris pump hit with another serious recall
A medical supply company is recalling BD (NYSE:BDX) Alaris infusion pumps — the third Class I recall for the pumps in recent months, according to the FDA. North Carolina-based Avante Health Solutions issued the Alaris pump recall March 24, 2021, because the bezel repair posts may crack or separate, leading to the inaccurate delivery of […]
BD applies to start shipping Alaris pumps again
BD (NYSE:BDX) said today that it has applied to the FDA for a new clearance for its recall-plagued Alaris infusion pump system. BD has had shipments of Alaris pumps on hold after the FDA called for a comprehensive 510(k) submission to cover a host of software fixes needed following a Class I-level recall in March […]
Pump problem prompts another Alaris recall
Days after classifying one recall for the Alaris infusion pump, the FDA has issued another Class I recall for the device. On Friday of last week, the FDA issued a Class I recall — the most serious kind — for the BD (NYSE:BDX) Alaris because there is a risk of the keypad lifting up due to […]
